 |
 |
 |
|
LONG TERM OUTCOME AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD) SUCCESSFULLY TREATED FOR HCV INFECTION WITH GLECAPREVIR/PIBRENTASVIR (G/P)
|
|
|
S. YI,1 C. WIESMANN,1,2 D. TRUONG,1 and B. CONWAY1,2
1. Vancouver Infectious Diseases Centre, Vancouver, Canada
2. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada





|
|
|
 |
 |
|
|